MGB: Finding its groove

MGB Biopharma developing minor groove binders against drug-resistant bacteria

It has been known for decades that compounds binding to the minor groove of DNA can kill bacteria, but safety issues have prevented their development as antibiotics. MGB Biopharma Ltd. believes its compounds will get around the safety issues by selectively entering bacterial cells instead of mammalian cells.

MGB was founded in 2009 based on research by Colin Suckling, a professor of chemistry at the University of Strathclyde who was using distamycin as a template for designing antibacterial compounds.

Distamycin was discovered in 1962 and has

Read the full 844 word article

How to gain access

Continue reading with a
two-week free trial.